Abstract
Liver cancer or hepatocellular carcinoma or HCC has been one of the most challenging cancers to treat. Endless number of attempts to evaluate chemotherapeutic interventions, almost all fell short of any improvement of survival. This is despite a subtle improvement of survival using FOLFOX. Tyrosine kinase inhibitors were the critical driver of novel therapeutics for the treatment of advanced HCC. With the development of sorafenib and lenvatinib in first line treatment, two other tyrosine kinase inhibitors regorafenib and cabozantinib add to anti-VEGF ramucirumab demonstrated improved outcome in the second line setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
